Compounds > capecitabine
Page last updated: 2024-08-24

capecitabine and yttrium radioisotopes

capecitabine has been researched along with yttrium radioisotopes in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's2 (33.33)24.3611
2020's3 (50.00)2.80

Authors

AuthorsStudies
Ayav, A; Habib, N; Jiao, LR1
Astsaturov, I; Ball, DS; Cade, DN; Cohen, SJ; Dickens, A; Konski, AA; Marlow, C; Meropol, NJ; Meyer, JE; Putnam, S; Yu, JQ1
Cengel, KA; Damjanov, N; Metz, DC; Soulen, MC; Teitelbaum, UR; van Houten, D1
Boudjema, K; Bourien, H; Campillo-Gimenez, B; Edeline, J; Garin, E; Rolland, Y; Trochet, M1
Ahmed, O; Baker, T; Fung, J; Hwang, G; Liao, CY; Patel, M; Pillai, A; Yu, Q1
Şener, N; Yakupoğlu, A1

Trials

1 trial(s) available for capecitabine and yttrium radioisotopes

ArticleYear
Phase I study of capecitabine combined with radioembolization using yttrium-90 resin microspheres (SIR-Spheres) in patients with advanced cancer.
    British journal of cancer, 2014, Jul-15, Volume: 111, Issue:2

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Cohort Studies; Deoxycytidine; Embolization, Therapeutic; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Microspheres; Middle Aged; Neoplasms; Prospective Studies; Yttrium Radioisotopes

2014

Other Studies

5 other study(ies) available for capecitabine and yttrium radioisotopes

ArticleYear
Portal hypertension secondary to 90Yttrium microspheres: an unknown complication.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Nov-10, Volume: 23, Issue:32

    Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Hepatectomy; Humans; Hypertension, Portal; Liver Neoplasms; Male; Microspheres; Organoplatinum Compounds; Oxaliplatin; Radiopharmaceuticals; Yttrium Radioisotopes

2005
Safety and Feasibility of Integrating Yttrium-90 Radioembolization With Capecitabine-Temozolomide for Grade 2 Liver-Dominant Metastatic Neuroendocrine Tumors.
    Pancreas, 2018, Volume: 47, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Embolization, Therapeutic; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Temozolomide; Thrombocytopenia; Yttrium Radioisotopes

2018
Selective Internal Radiation Therapy (Yttrium-90 Glass Microspheres) Combined with Capecitabine in the Neoadjuvant Setting of Operable Intrahepatic CHOlangiocarcinoma: The SIROCHO Trial Design.
    Annals of surgical oncology, 2023, Volume: 30, Issue:1

    Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Humans; Radiopharmaceuticals

2023
Yttrium-90 Radioembolization and Concomitant Systemic Gemcitabine, Cisplatin, and Capecitabine as the First-Line Therapy for Locally Advanced Intrahepatic Cholangiocarcinoma.
    Journal of vascular and interventional radiology : JVIR, 2023, Volume: 34, Issue:4

    Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Cisplatin; Gemcitabine; Humans; Retrospective Studies; Treatment Outcome; Yttrium Radioisotopes

2023
Yttrium-90 transarterial radioembolization and capecitabine in hepatocellular carcinoma with portal vein involvement.
    Medicine, 2023, Sep-01, Volume: 102, Issue:35

    Topics: Capecitabine; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Portal Vein; Retrospective Studies

2023